A case of lymphocytic myocarditis in a patient treated with an immune checkpoint inhibitor, a recent class of chemotherapy agents

Autor: Tatiana Duarte, Cátia Costa, Sara Gonçalves, Luís Raposo, António Ferreira, Catarina Albuquerque, Nuno Vau, Rui Caria

Publikováno v: Revista Portuguesa de Cardiologia, Vol 41, Iss 12, Pp 1047-1051 (2022)

Chemotherapy-associated cardiotoxicity is a common adverse event. Immune checkpoint inhibitors (ICI) – a new class of monoclonal antibodies – have revolutionized the management of various diseases. Their use is expected to increase in the near fu

Externí odkaz: https://doaj.org/article/fdac67f0b87f4234a9715c93bcf88bb3

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

Autor: Matteo Santoni, Zin W. Myint, Thomas Büttner, Hideki Takeshita, Yohei Okada, Elaine T. Lam, Danielle Gilbert, Zsófia Küronya, Deniz Tural, Renate Pichler, Enrique Grande, Simon J. Crabb, Robert Kemp, Francesco Massari, Sarah Scagliarini, Roberto Iacovelli, Nuno Vau, Umberto Basso, Marco Maruzzo, Javier Molina-Cerrillo, Luca Galli, Aristotelis Bamias, Ugo De Giorgi, Paolo Andrea Zucali, Mimma Rizzo, Emmanuel Seront, Lazar Popovic, Orazio Caffo, Sebastiano Buti, Ravindran Kanesvaran, Jindrich Kopecky, Jakub Kucharz, Annalisa Zeppellini, Ondřej Fiala, Johannes Landmesser, Jawaher Ansari, Patrizia Giannatempo, Alessandro Rizzo, Ignacio Ortego Zabalza, Fernando Sabino M. Monteiro, Nicola Battelli, Fabio Calabrò, Camillo Porta

Publikováno v: Cancer Immunology, Immunotherapy.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d073e80624dad7dc9971e9ffe0fbfa8d
https://doi.org/10.1007/s00262-023-03469-5

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

Autor: Matteo Santoni, Francesco Massari, Sergio Bracarda, Giuseppe Procopio, Michele Milella, Ugo De Giorgi, Umberto Basso, Gaetano Aurilio, Lorena Incorvaia, Angelo Martignetti, Mimma Rizzo, Giacomo Cartenì, Enrique Grande, Marc R. Matrana, Simon J. Crabb, Nuno Vau, Giulia Sorgentoni, Alessia Cimadamore, Rodolfo Montironi, Nicola Battelli

Publikováno v: Diagnostics, Vol 11, Iss 1, p 138 (2021)

We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Ove

Externí odkaz: https://doaj.org/article/cd77ceade10e4683b7d74e70f060dee7

Immune checkpoint inhibitors for the treatment of bladder cancer

Autor: Rodolfo Montironi, Marina Scarpelli, Ana Blanca, Nuno Vau, Francesco Massari, Liang Cheng, Alessia Cimadamore, Antonio Lopez-Beltran

Publikováno v: Cancers, Vol 13, Iss 131, p 131 (2021)
Cancers 13(1), 131 (2021)
Helvia: Repositorio Institucional de la Universidad de Córdoba
Universidad de Córdoba
Cancers
Helvia. Repositorio Institucional de la Universidad de Córdoba
Universidad de Cantabria (UC)

Simple Summary In this review, we examined relevant clinical trial results with immune checkpoint inhibitors in patients with metastatic urothelial cancer. We also focused on the potential of immunotherapy in the adjuvant and neoadjuvant setting or a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e43df31ac1e76f80af64ebab6f7a2416
https://hdl.handle.net/11390/1242925

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

Autor: Alessia Cimadamore, Camillo Porta, Giacomo Cartenì, Paolo Andrea Zucali, Cinzia Ortega, Roberto Iacovelli, Matteo Santoni, Daniele Santini, Alessandra Mosca, Erin Pierce, Marc R. Matrana, Elena Verzoni, Orazio Caffo, Michele Milella, Rodolfo Montironi, Sebastiano Buti, Jeffrey Graham, Sara Merler, Francesco Carrozza, Sergio Bracarda, Marina Scarpelli, Umberto Basso, Francesco Massari, Francesco Piva, Liang Cheng, Vittorio Paolucci, Angelo Martignetti, Franco Morelli, Cristina Masini, Fabio Calabrò, Giuseppe Fornarini, Sarah Scagliarini, Lorena Incorvaia, Nuno Vau, Mimma Rizzo, Francesco Atzori, Alain Gelibter, Riccardo Ricotta, Antonio Lopez-Beltran, Maria Giuseppa Vitale, Ugo De Giorgi, Simon J. Crabb, Giulia Sorgentoni, Pierangela Sepe, Luca Galli, Giuseppe Procopio, Daniel Y. Heng, Alessandro Conti, Nicola Battelli

Publikováno v: Cancers
Volume 12
Issue 1
Cancers, Vol 12, Iss 1, p 84 (2019)

Cabozantinib is approved for the treatment of renal cell carcinoma (RCC). However, prognostic factors are still lacking in this context. The aim of this study was to evaluate prognostic factors in RCC patients treated with second- or third-line caboz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cb195a8a2a20780d892ff3b9eccb944